UBS Reiterates Buy Rating on Repligen (RGEN) as Incrementally Positive on Outlook
Tweet Send to a Friend
UBS analyst Douglas Schenkel reiterated a Buy rating and $225.00 price target on Repligen (NASDAQ: RGEN).The analyst commented, "Our recent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




